Chrystal Paulos to Neoplasms
This is a "connection" page, showing publications Chrystal Paulos has written about Neoplasms.
Connection Strength
3.702
-
Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy. Front Immunol. 2021; 12:645242.
Score: 0.333
-
Identification of human CD4+ T cell populations with distinct antitumor activity. Sci Adv. 2020 07; 6(27).
Score: 0.317
-
IL6 Fuels Durable Memory for Th17 Cell-Mediated Responses to Tumors. Cancer Res. 2020 09 15; 80(18):3920-3932.
Score: 0.317
-
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines. Front Immunol. 2019; 10:263.
Score: 0.289
-
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. Front Immunol. 2018; 9:1740.
Score: 0.278
-
When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018 May; 15(5):458-469.
Score: 0.271
-
Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nat Commun. 2017 12 06; 8(1):1961.
Score: 0.266
-
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother. 2016 Mar; 65(3):247-59.
Score: 0.234
-
Harnessing the Microbiome to Enhance Cancer Immunotherapy. J Immunol Res. 2015; 2015:368736.
Score: 0.223
-
Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. J Clin Invest. 2010 Jan; 120(1):76-80.
Score: 0.153
-
Toll-like receptors in tumor immunotherapy. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5280-9.
Score: 0.131
-
Stress-Mediated Attenuation of Translation Undermines T-cell Activity in Cancer. Cancer Res. 2022 12 02; 82(23):4386-4399.
Score: 0.094
-
Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-? (ROR?) Agonist for Use in Treating Cancer. J Med Chem. 2021 09 23; 64(18):13410-13428.
Score: 0.086
-
The evolving landscape of immunotherapy in solid tumors. J Surg Oncol. 2021 Mar; 123(3):798-806.
Score: 0.083
-
RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity. Sci Adv. 2020 05; 6(22):eaaz3865.
Score: 0.079
-
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy). J Immunother Cancer. 2019 11 29; 7(1):332.
Score: 0.076
-
Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018 07 11; 6(1):69.
Score: 0.069
-
IL-2 and Beyond in Cancer Immunotherapy. J Interferon Cytokine Res. 2018 02; 38(2):45-68.
Score: 0.067
-
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metab. 2018 01 09; 27(1):85-100.e8.
Score: 0.066
-
Modulation of Endoplasmic Reticulum Stress Controls CD4+ T-cell Activation and Antitumor Function. Cancer Immunol Res. 2017 08; 5(8):666-675.
Score: 0.064
-
Reducing CD73 expression by IL1?-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 2014 Nov 01; 74(21):6048-59.
Score: 0.053
-
The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med. 2010 Oct 27; 2(55):55ra78.
Score: 0.041
-
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010 Jan; 33(1):1-7.
Score: 0.038
-
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008 Jun 10; 105(23):8061-6.
Score: 0.034
-
Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res. 2008; 42(1-3):182-96.
Score: 0.033
-
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol. 2006 May 01; 176(9):5255-66.
Score: 0.007